Navigating Disease-Modifying Treatments for Alzheimer’s Disease: Focusing on Medications in Phase 3 Clinical Trials

Abstract

Over the past 18 months, there has been scrutiny and controversy over the U.S. Food and Drug Administration’s accelerated approval of aducanumab, a novel monoclonal antibody to treat Alzheimer’s disease and prevent disease progression. As clinicians, educators, and advocates for our patients and caregivers impacted daily by this debilitating illness, this approval reinforces the need to maintain vigilance and awareness about emerging agents. The intent of the current article is to highlight some of the medications in Phase 3 clinical trials and share resources and updates on disease-modifying agents and their unique pharmacology.